Centessa Pharmaceuticals (CNTA) Competitors

DICE Therapeutics (NASDAQ:DICE) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.

Do institutionals & insiders have more ownership in DICE or CNTA?

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.9% of DICE Therapeutics shares are owned by insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community favor DICE or CNTA?

Centessa Pharmaceuticals received 13 more outperform votes than DICE Therapeutics when rated by MarketBeat users. Likewise, 56.86% of users gave Centessa Pharmaceuticals an outperform vote while only 40.00% of users gave DICE Therapeutics an outperform vote.

Company	Underperform	Outperform
DICE Therapeutics	Outperform Votes 16 40.00%	Underperform Votes 24 60.00%
Centessa Pharmaceuticals	Outperform Votes 29 56.86%	Underperform Votes 22 43.14%

Is DICE or CNTA more profitable?

DICE Therapeutics' return on equity of -22.01% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DICE Therapeutics	N/A	-22.01%	-20.79%
Centessa Pharmaceuticals	N/A	-52.13%	-38.01%

Which has preferable earnings and valuation, DICE or CNTA?

DICE Therapeutics has higher earnings, but lower revenue than Centessa Pharmaceuticals. DICE Therapeutics is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DICE Therapeutics	$1.13M	2,008.50	-$83.89M	-$2.34	-20.32
Centessa Pharmaceuticals	$6.85M	281.87	-$151.09M	-$1.53	-11.14

Does the media prefer DICE or CNTA?

In the previous week, Centessa Pharmaceuticals had 10 more articles in the media than DICE Therapeutics. MarketBeat recorded 10 mentions for Centessa Pharmaceuticals and 0 mentions for DICE Therapeutics. Centessa Pharmaceuticals' average media sentiment score of 0.76 beat DICE Therapeutics' score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
DICE Therapeutics	Neutral
Centessa Pharmaceuticals	Positive

Which has more risk and volatility, DICE or CNTA?

DICE Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Do analysts prefer DICE or CNTA?

Centessa Pharmaceuticals has a consensus target price of $25.83, indicating a potential upside of 51.60%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than DICE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DICE Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Centessa Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Centessa Pharmaceuticals beats DICE Therapeutics on 13 of the 17 factors compared between the two stocks.